A Food and Drug Administration advisory committee on Tuesday recommended approval of a new type of experimental cholesterol-fighting drug that could be more potent and carry fewer side effects than statins, which are among the most prescribed drugs in the United States. The agency will likely follow the advisory committee’s advice when it decides whether to approve the drug, alirocumab from Sanofi SA and Regeneron Pharmaceuticals Inc., for patients later this summer.